Illimis Therapeutics

Every anti-amyloid drug approved for Alzheimer's shares a stubborn flaw. They strip plaque from the brain, but often at a cost: ARIA - amyloid-related imaging abnormalities, the swelling and micro-bleeds that show up on brain scans and force doctors to monitor patients closely. Illimis Therapeutics, a biotechnology company founded in Seoul in 2021, was built around a different question. What if you could clear the plaque without picking a fight with the immune system?

The answer is a platform the company calls GAIA - short for Gas6-mediated Anti-Inflammatory Adaptor. Rather than flagging amyloid for an inflammatory attack, GAIA hands it to the body's cleanup crew and asks them to digest it quietly, the same way the body disposes of billions of dead cells every day.

That process - efferocytosis - is one of biology's oldest housekeeping tricks. Illimis is trying to turn it into medicine. The company pairs deep science with an unusually global footprint: research headquarters in Seoul, a subsidiary in Boston, an advisory bench that includes a founding figure in TAM-receptor biology, and a collaboration with Eli Lilly, one of the few companies to actually bring an Alzheimer's antibody to market.

In July 2025, Illimis closed a $42 million Series B backed by 18 investors - a notable vote of confidence during a lean stretch for biotech funding, and enough to push its lead candidate toward first-in-human trials.

In preclinical models, Illimis ran its GAIA construct head-to-head against aducanumab - the first FDA-approved anti-amyloid antibody, later withdrawn amid debate over its side effects and benefit.

The company reported greater cognitive improvement alongside markedly lower inflammatory response and reduced ARIA. These are preclinical, animal-model results - not clinical proof - but they define the exact claim Illimis is racing to test in humans by 2027.

Bars below are a schematic illustration of the company's stated preclinical direction, not published trial percentages.

On July 14, 2025, Illimis closed a 58 billion KRW ($42 million) Series B - bringing total funding to roughly $65.4 million. Eight existing investors returned; ten new ones joined.

The round is a business-model tell. Pre-commercial biotechs like Illimis run on equity and grants, converting capital into clinical progress and, eventually, into partnering deals with large pharma. The presence of the Korea Development Bank and the Industrial Bank of Korea alongside venture funds signals both institutional and strategic backing.

Alzheimer's is one of medicine's largest unmet needs, and the anti-amyloid field is crowded at the top: Eisai and Biogen's lecanemab (Leqembi) and Eli Lilly's donanemab (Kisunla) are on the market, both carrying ARIA warnings.

Illimis is not trying to build a slightly better antibody. It is competing on mechanism - clearance via phagocytosis instead of inflammatory tagging. That places it near other differentiated neuro-immune approaches, such as TREM2 agonists and microglia-modulating biotechs, rather than in a straight race with the incumbents.

For patients and the physicians who treat them, the promise is simple to state and hard to deliver: the benefit of plaque removal with less of the monitoring burden and risk that comes with today's drugs. For pharma partners, GAIA offers a reusable engine that could be pointed at tau, alpha-synuclein, or immune targets.

The catch, as with all preclinical-stage biotech, is that the story is still unproven in humans. The 2027 IND is the moment the thesis meets the clinic.